Fig. 10From: Identification and validation of an immune-associated RNA-binding proteins signature to predict clinical outcomes and therapeutic responses in colon cancer patientsDrug sensitivity analysis of two RBPs (FBXO17 and PPARGC1A). FBXO17 expression was negatively associated with b Palbociclib, c PX-31, j Perifosine, k LDK-378, m Entinostat drug sensitivity, and positively related to e Bleomycin, g Gemcitabine, h Irofulven, o Sonidegib, and p Lenvatinib drug sensitivity. PPARGC1A expression was negatively related to d Triciribine phosphate, f 7-Hydroxystaurosporine, and l Dasatinib drug sensitivity, and positively related to a Dabrafenib, i Vemurafenib, and n Hydrastinine HCl drug sensitivity. X-axis is gene expression; Y-axis is IC50 of each drugBack to article page